A Multicenter Open-Label Phase 1B/2 Study Of The Bruton?S Tyrosine (Btk) Inhibitor, Ibrutinib, In Combination With Lenalidomide And Rituximab In Subje
Posted Date: May 15, 2019
- Investigator: Tahir Latif
- Type of Study: Drug
Pharmacyclics PCYC-1123-CA
Criteria:
To Be Eligible To Participate In This Study, Participants Must Have A Form Of Cancer Called Diffuse
Keywords:
Cancer, Hem Malignancy, Lymphoma, Pcyc-1123-Ca, Phase Ib/Ii
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com